IL123294A0 - Monoclonal antibody BR110 and uses thereof - Google Patents

Monoclonal antibody BR110 and uses thereof

Info

Publication number
IL123294A0
IL123294A0 IL12329496A IL12329496A IL123294A0 IL 123294 A0 IL123294 A0 IL 123294A0 IL 12329496 A IL12329496 A IL 12329496A IL 12329496 A IL12329496 A IL 12329496A IL 123294 A0 IL123294 A0 IL 123294A0
Authority
IL
Israel
Prior art keywords
antigen
monoclonal antibody
complex
ligands
ligand
Prior art date
Application number
IL12329496A
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of IL123294A0 publication Critical patent/IL123294A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL12329496A 1995-10-19 1996-10-07 Monoclonal antibody BR110 and uses thereof IL123294A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US564195P 1995-10-19 1995-10-19
PCT/US1996/016070 WO1997014796A1 (en) 1995-10-19 1996-10-07 Monoclonal antibody br110 and uses thereof

Publications (1)

Publication Number Publication Date
IL123294A0 true IL123294A0 (en) 1998-09-24

Family

ID=21716930

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12329496A IL123294A0 (en) 1995-10-19 1996-10-07 Monoclonal antibody BR110 and uses thereof

Country Status (11)

Country Link
US (1) US5840854A (xx)
EP (1) EP0856054B1 (xx)
JP (1) JP2001501801A (xx)
AT (1) ATE265532T1 (xx)
AU (1) AU7394296A (xx)
CA (1) CA2235269C (xx)
DE (1) DE69632333T2 (xx)
ES (1) ES2219699T3 (xx)
IL (1) IL123294A0 (xx)
NO (1) NO321548B1 (xx)
WO (1) WO1997014796A1 (xx)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7354587B1 (en) * 1994-07-06 2008-04-08 Immunomedics, Inc. Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US6366762B1 (en) * 1999-03-31 2002-04-02 Qualcomm, Inc. System and method for measuring round trip delay on the paging and access channels
US6617432B1 (en) * 1999-10-15 2003-09-09 University Of Pittsburgh Nuclear matrix proteins polynucleotide sequences encoding them and their use
US20030009781A1 (en) * 2001-03-29 2003-01-09 Allen Keith D. Transgenic mice containing Kir3.3 potassium channel gene disruptions
US20020155109A1 (en) * 2001-04-20 2002-10-24 Lynch David H. Bispecific antibodies that bind TRAIL-R1 and TRAIL-R2
US8435529B2 (en) 2002-06-14 2013-05-07 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
US9745380B2 (en) 2002-03-01 2017-08-29 Immunomedics, Inc. RS7 antibodies
DE60325184D1 (de) 2002-03-01 2009-01-22 Immunomedics Inc Rs7 antikörper
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
US9701754B1 (en) 2002-10-23 2017-07-11 City Of Hope Covalent disulfide-linked diabodies and uses thereof
US20080305104A1 (en) * 2006-02-24 2008-12-11 Young David S F Cytotoxicity mediation of cells evidencing surface expression of TROP-2
US7420040B2 (en) * 2006-02-24 2008-09-02 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
US20080131428A1 (en) * 2006-02-24 2008-06-05 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
US20080213267A1 (en) * 2006-02-24 2008-09-04 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
CA2646329C (en) 2006-03-20 2018-07-03 The Regents Of The University Of California Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
JP4689521B2 (ja) * 2006-04-07 2011-05-25 財団法人電力中央研究所 抗鉛モノクローナル抗体
US8940298B2 (en) 2007-09-04 2015-01-27 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
ES2712732T3 (es) 2009-02-17 2019-05-14 Cornell Res Foundation Inc Métodos y kits para el diagnóstico de cáncer y la predicción de valor terapéutico
CA2782333C (en) 2009-12-02 2019-06-04 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
SG10201503904XA (en) * 2010-05-17 2015-06-29 Livtech Inc Anti-human trop-2 antibody having antitumor activity in vivo
WO2011155579A1 (ja) * 2010-06-10 2011-12-15 北海道公立大学法人札幌医科大学 抗Ｔｒｏｐ－２抗体
SG11201401699WA (en) 2011-11-11 2014-09-26 Rinat Neuroscience Corp Antibodies specific for trop-2 and their uses
US9427464B2 (en) 2011-11-22 2016-08-30 Chiome Bioscience Inc. Anti-human TROP-2 antibody having an antitumor activity in vivo
CN106132436B (zh) 2014-02-21 2021-06-15 Ibc药品公司 通过诱导对trop-2表达细胞的免疫应答的疾病疗法
EP3286224A4 (en) 2015-04-22 2018-11-14 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
AU2016304764C1 (en) 2015-08-07 2023-06-01 Imaginab, Inc. Antigen binding constructs to target molecules
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
CN113260384A (zh) 2018-11-05 2021-08-13 西纳福克斯股份有限公司 用于靶向表达trop-2的肿瘤的抗体缀合物
CN115398010A (zh) 2020-03-20 2022-11-25 免疫医疗公司 用于戈沙妥珠单抗疗法的生物标志物
CA3194725A1 (en) 2020-10-14 2022-04-21 Dongjie MAO Anti-trop-2 antibody, antigen-binding fragment thereof or mutant thereof, and medical use thereof
CN117295524A (zh) 2021-06-02 2023-12-26 百奥泰生物制药股份有限公司 药物偶联物及其用途
AU2022350725A1 (en) 2021-09-23 2024-03-28 Changzhou Hansoh Pharmaceutical Co., Ltd. Antibody-drug conjugate, preparation method therefor, and pharmaceutical use thereof
WO2023180485A1 (en) 2022-03-23 2023-09-28 Synaffix B.V. Antibody-conjugates for targeting of tumours expressing trop-2

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185254A (en) * 1988-12-29 1993-02-09 The Wistar Institute Gene family of tumor-associated antigens
AU641392B2 (en) * 1989-04-21 1993-09-23 Protein Design Laboratories, Inc. Recombinant antibody-toxin fusion protein
EP0609292A4 (en) * 1991-10-18 1995-10-25 Wistar Inst Soluble variants of type i membrane proteins, and methods of using them.

Also Published As

Publication number Publication date
US5840854A (en) 1998-11-24
CA2235269C (en) 2006-09-19
EP0856054B1 (en) 2004-04-28
CA2235269A1 (en) 1997-04-24
MX9802129A (es) 1998-05-31
ATE265532T1 (de) 2004-05-15
DE69632333T2 (de) 2004-12-30
NO981745D0 (no) 1998-04-17
NO981745L (no) 1998-04-17
DE69632333D1 (de) 2004-06-03
NO321548B1 (no) 2006-05-29
JP2001501801A (ja) 2001-02-13
ES2219699T3 (es) 2004-12-01
EP0856054A1 (en) 1998-08-05
WO1997014796A1 (en) 1997-04-24
AU7394296A (en) 1997-05-07

Similar Documents

Publication Publication Date Title
IL123294A0 (en) Monoclonal antibody BR110 and uses thereof
WO1997046589A3 (en) Humanized antibodies that bind to the same antigen as bound by antibody nr-lu-13, and their use in pretargeting methods
ES2106195T3 (es) Anticuerpo igg aglicosilado anti cd3.
AU6954398A (en) Antagonistic anti-avb3 integrin antibodies
EP0724456A4 (en) ANTIBODIES AGAINST CD40
AU2001257012A1 (en) Methods for selective targeting
GEP20105118B (en) Anti-vegf antibodies
AU8432498A (en) Human-cd28 specific monoclonal antibodies for antigen non-specific activation oft-lymphocytes
GB2383331A (en) Monoclonal antibody DS6 Tumor-associated antigen CA6 and methods of use thereof
EP1071460A4 (en) INTERNALIZING ERB2 ANTIBODIES
CA2442182A1 (en) Modulation of pd-1 interactions with its ligands
WO2004025248A3 (en) Antibody pair screening methods
IL162117A0 (en) Humanized collagen antibodies and methods utilizing the same
ATE248859T1 (de) Metallion-ligand koordinationskomplexe, antikorper dagegen und tests die solche antikorper verwenden
AU4441799A (en) Monoclonal antibodies that recognize antigens associated with tumor metastasis
WO2005046597A3 (en) Antibodies to cd44 glycoforms and uses thereof
IL108607A0 (en) Preparation of photoprotein conjugates and methods of use thereof
WO2003072727A3 (en) EGFRvIII SPECIFIC MONOCLONAL ANTIBODY AND EGFRvIII RIBOZYMES AND USE TO DETECT, TREAT OR PREVENT EGFRvIII ASSOCIATED CANCER
GB2307041B (en) Sheets,kits and methods for detecting antigens or antibodies
AU5924699A (en) Methods for identifying hot-spot residues of binding proteins and small compounds that bind to the same
DE59608073D1 (de) Antikörper gegen ein, einen histidin-anteil aufweisendes fusionspolypeptid
GB9721432D0 (en) Improved production of antibodies through the use of antigen antibody complexes
NO20001051D0 (no) Monoklonale antistoffer som binder testosteron
AU6068000A (en) Peptide ligands that bind igm antibodies and block interaction with antigen
AU9161991A (en) Carcinoma orosomucoid-related antigen, a monoclonal antibody thereto, and their uses